Page last updated: 2024-12-08

yamogenin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID441900
CHEMBL ID400807
CHEBI ID10086
SCHEMBL ID6040875
MeSH IDM0503063

Synonyms (36)

Synonym
nsc-226132
yamogenin
C08918
512-06-1
CHEMBL400807
chebi:10086 ,
LMST01080045
(25s)-spirost-5-en-3beta-ol
nsc 226132
spirost-5-en-3-ol, (3beta,25s)-
neodiosgenin
jamogenin
unii-m487od4xw3
25-epi-diosgenin
m487od4xw3 ,
S5675
(2r,5's)-5'-tetramethylspiro[[?]-2,2'-tetrahydropyran]ol
SCHEMBL6040875
AKOS025402417
AC-8895
WQLVFSAGQJTQCK-CAKNJAFZSA-N
(22r,25s)-(20.alpha.)-spirost-5-en-3.beta.-ol
spirost-5-en-3-ol, (3.beta.,25s)-
(20alpha,22r,25s)-spirosta-5-ene-3beta-ol
(2'r,4s,5's,6ar,6bs,8as,8br,9s,11as,12as,12bs)-5',6a,8a,9-tetramethyl-1,3,3',4,4',5,5',6,6a,6b,6',7,8,8a,8b,9,11a,12,12a,12b-icosahydrospiro[naphtho[2',1':4,5]indeno[2,1-b]furan-10,2'-pyran]-4-ol
HY-N2078
Q8048088
CS-0018583
DTXSID60903922 ,
(1s,2s,4s,5's,6r,7s,8r,9s,12s,13r,16s)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-ol
yamogenin - 70%
XY165194
bdbm604165
us11660306, example yamogenin
(22r,25s)-(20alpha)-spirost-5-en-3beta-ol
dtxcid201331882

Research Excerpts

Overview

Yamogenin is a diastereomer of diosgenin, which we have identified as the compound responsible for the anti-hyperlipidemic effect of fenugreek.

ExcerptReferenceRelevance
"Yamogenin is a diastereomer of diosgenin, which we have identified as the compound responsible for the anti-hyperlipidemic effect of fenugreek. "( Yamogenin in fenugreek inhibits lipid accumulation through the suppression of gene expression in fatty acid synthesis in hepatocytes.
Goto, T; Hoshino, S; Kawada, T; Moriwaki, S; Murakami, H; Narukami, T; Takahashi, N; Taketani, K; Tsuge, N; Uemura, T, 2014
)
3.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
triterpenoidAny terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID744419Cytotoxicity against human MDA-MB-231 cells2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Spirostanoids with 1,4-dien-3-one or 3β,7α-diol-5,6-ene moieties from Solanum violaceum.
AID744418Cytotoxicity against human A549 cells2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Spirostanoids with 1,4-dien-3-one or 3β,7α-diol-5,6-ene moieties from Solanum violaceum.
AID744421Cytotoxicity against human HepG2 cells2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Spirostanoids with 1,4-dien-3-one or 3β,7α-diol-5,6-ene moieties from Solanum violaceum.
AID744420Cytotoxicity against human MCF7 cells2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Spirostanoids with 1,4-dien-3-one or 3β,7α-diol-5,6-ene moieties from Solanum violaceum.
AID744422Cytotoxicity against human Hep3B cells2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Spirostanoids with 1,4-dien-3-one or 3β,7α-diol-5,6-ene moieties from Solanum violaceum.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (38.89)18.7374
1990's2 (11.11)18.2507
2000's3 (16.67)29.6817
2010's5 (27.78)24.3611
2020's1 (5.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.92 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]